PARP Inhibitor Biomarkers Market Size is valued at USD 897.8 Mn in 2023 and is predicted to reach USD 1,751.6 Mn by the year 2031 at a 8.8% CAGR during the forecast period for 2024-2031.
These biomarkers play a critical role in informing treatment decisions and identifying patients who are at the highest risk of benefiting from PARP inhibitor therapy. In order to detect these markers, genomic profiling or specific genetic assays are frequently employed. The growth of the PARP (poly-ADP ribose polymerase) inhibitor biomarkers market is attributed to several factors, including the increasing occurence of breast cancer, advancements in genetic technologies, and rising expenditures for oncology treatments. Research and development efforts aimed at novel therapies are expected to propel the global PARP inhibitor biomarkers market during the forecast period.
Their research suggests that combining chemotherapy with PARP inhibitors can effectively suppress the proliferation of cancer cells and induce their destruction. Consequently, the growing focus on cancer treatment research and development is anticipated to create lucrative opportunities for manufacturers to introduce new products and developments to the market. Furthermore, the expansion is attributed to the substantial rise in investments in PARP inhibitor biomarkers technologies throughout the region, accompanied by an increase in per capita income, which drives the greater adoption of diagnostic and therapeutic products. Government initiatives aimed at enhancing healthcare infrastructure further contribute to the anticipated regional growth.
Competitive Landscape
Some Major Key Players In The PARP Inhibitor Biomarkers Market:
- Myriad Genetics, Inc.
- Ambry Genetics
- Thermo Fisher Scientific, Inc.
- Illumina, Inc.
- CENTOGENE N.V.
- Amoy Diagnostics Co., Ltd.
- Invitae Corporation
- NeoGenomics Laboratories.
- QIAGEN
- Agilent Technologies, Inc.
- Hoffmann-La Roche AG
- Bio Rad Laboratories Inc.,
- Exagen Inc.,
- Genway Biotech, Inc.,
- Svar Life Science AB
- Siemens Healthcare GmbH,
- Other Market Players
Market Segmentation:
The PARP Inhibitor Biomarkers market is segmented by product, services and application. As per the product, the market is segmented as kits and Assays. By services, the market is bifurcated into BRCA 1 & 2 Testing, HRD Testing, HRR Testing, and Others. The application segment includes Breast Cancer, Ovarian Cancer, and Others.
The Assay Category From Product Segment Is A Major Contributor To The Market.
The assay segment is poised to dominate the PARP Inhibitor Biomarkers market throughout the forecast period. This assay assesses the comparative specificity of PARP inhibitors and analyzes the levels of ADP-ribosylation by individual PARPs across different conditions. It serves as a valuable asset in research and development settings, facilitating the investigation of the effects of PARP inhibitors on cancer cells or the creation of novel assays for potential clinical use.
The Breast Cancer Segment Witnessed Growth At A Rapid Rate.
The breast cancer sector is anticipated to dominate the market. Breast cancer represents a prevalent cancer type among women, standing as the primary cause of cancer-related fatalities in females across 95% of nations. However, survival rates exhibit substantial variance, with a notable majority of fatalities occurring in low- and middle-income countries. While high-income nations have experienced marked declines in breast cancer mortality rates over recent decades, comparable progress has not been realized in low- and middle-income nations. This discrepancy in survival rates primarily stems from late-stage diagnoses, inadequate diagnostic and treatment resources, and the absence of breast cancer coverage under universal health schemes in these regions.
In The Region, North American PARP Inhibitor Biomarkers Hold A Significant Revenue Share.
North America is expected to become the dominant area in the global PARP Inhibitor Biomarkers market. Healthcare professionals and patients in North America are increasingly recognizing the importance of biomarkers in personalized medicine and targeted therapy. This increased awareness translates into a rising demand for PARP inhibitor biomarkers in clinical settings, further propelling market growth across the region.
In summary, the anticipated significant market share of the North American PARP Inhibitor Biomarkers Market is underpinned by its advanced healthcare infrastructure, high cancer incidence, robust research and development landscape, regulatory support, and escalating awareness and adoption of biomarker-guided therapies. Additionally, APAC region dominance stems from an increasing focus on environmentally friendly building practices and a surge in the demand for sustainable construction solutions. Additionally, the growing adoption of devices featuring advanced capabilities in emerging economies like China, Japan, and India is projected to propel market expansion during the forecast period.
Recent Developments:
- In April 2024, Bio-Rad Laboratories, Inc. introduced its inaugural ultrasensitive multiplexed digital PCR assay, known as the ddPLEX ESR1 Mutation Detection Kit. The assay enhanced the company's Droplet Digital PCR (ddPCR™) product line for the field of oncology. These mutation detection assays are very sensitive and capable of detecting several mutations simultaneously. They are valuable for translational research, selecting appropriate therapies, and monitoring disease progression.
- In February 2024, Myriad Genetics, Inc., a renowned genetic testing and precision medicine firm, successfully finalized the acquisition of specific assets from Intermountain Health's Intermountain Precision Genomics (IPG) laboratory business. This acquisition encompasses Precision Oncology Testing, Precision Fluid Testing, and their CLIA-certified laboratory based in St. George, Utah.
PARP Inhibitor Biomarkers Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 897.8 Mn |
|
Revenue Forecast In 2031 |
USD 1,751.6 Mn |
|
Growth Rate CAGR |
CAGR of 8.8% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Product, Services and Application |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Myriad Genetics, Inc., AmbryGenetics, Thermo Fisher Scientific Inc., Illumina, Inc., CENTOGENE N.V., Amoy Diagnostics Co., Ltd.; Invitae Corporation, NeoGenomics Laboratories., QIAGEN, Agilent Technologies, Inc., F. Hoffmann-La Roche AG, Bio Rad Laboratories Inc., Exagen Inc., Genway Biotech, Inc., Svar Life Science AB, Siemens Healthcare GmbH, Other Market Players |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
